RecruitingNot applicableNCT07681388
Dermatological
Pemphigus Vulgaris
Also known as PV, autoimmune blistering, desmoglein 3 antibody, mucosal pemphigus
Pemphigus vulgaris is a potentially life-threatening autoimmune blistering disorder characterised by circulating IgG autoantibodies directed against desmoglein 3 and, in cutaneous disease, desmoglein 1 — desmosomal cadherins essential for k
6
studies recruiting now
as of 7 Sept 2026
48
studies registered in total
as of 7 Sept 2026
4
countries with a recruiting site
as of 7 Sept 2026
2 Jul 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNot applicableNCT07641725
Comparison of the Efficacy of Clobetasol Propionate 0.05% Mouthwash, Photobiomodulation, and Their Combination in Managing of Oral Lesions in Patient With Pemphigus Vulgaris.
RecruitingPhase 1 / Phase 2NCT04422912
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
RecruitingNCT02753777
Autoimmune Blistering Diseases Study
RecruitingNCT07384221
Periodontal Status and Disease Severity in Pemphigus Vulgaris Patients
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 6 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Pemphigus Vulgaris study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: IPPF Patient Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Pemphigus Vulgaris
Pemphigus vulgaris is a potentially life-threatening autoimmune blistering disorder characterised by circulating IgG autoantibodies directed against desmoglein 3 and, in cutaneous disease, desmoglein 1 — desmosomal cadherins essential for keratinocyte adhesion. Loss of epidermal and mucosal cohesion results in suprabasal acantholysis and flaccid blisters that rupture easily, leaving painful, slow-healing erosions predominantly on mucous membranes and the skin. Without immunosuppressive treatment the condition is chronic and progressive; historically fatal, it now carries significant morbidity from both the disease and its treatments.
Common clinical features
Painful oral mucosal erosions, frequently the presenting symptom, preceding skin involvement by monthsFlaccid, thin-walled blisters on non-inflamed or erythematous skin that rupture rapidlyWidespread erosions on the trunk, scalp, face, and flexures that are slow to healPositive Nikolsky sign: lateral pressure on perilesional skin induces blister extensionOesophageal and pharyngeal erosions causing dysphagia and odynophagiaConjunctival and genital mucosal erosions in severe casesSignificant weight loss and nutritional compromise from painful oral and oesophageal involvement
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
3 approved treatments and 13 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Approved: Dexamethasone (Aeroseb-dex)Approved: Prednisone (Cortan)Approved: Dexamethasone Sodium Phosphate (Ak-dex)
Phase 3Mycophenolate Mofetil (Arzip)
Phase 3Ofatumumab (Arzerra)
Phase 3Rituximab (Blitzima)
Phase 3Triamcinolone Acetonide (Adcortyl)
Phase 2Azathioprine (Azamune)
Phase 2Parsaclisib
Phase 2Itx-5061
Phase 2Etanercept (Benepali)
+ 5 more in development
Before you apply
Things trial teams commonly ask about for Pemphigus Vulgaris. Not eligibility rules; those are set by each study.
- Trials typically require serological confirmation with anti-desmoglein 3 (and/or anti-desmoglein 1) ELISA titres at screening — ensure recent antibody levels are documented within the protocol-specified timeframe.
- Disease severity grading using the Pemphigus Disease Area Index (PDAI) is the standard outcome measure; understand your baseline PDAI score as minimum severity thresholds are common eligibility criteria.
- Prior rituximab use and timing since last infusion is frequently an exclusion criterion or stratification factor; provide a complete biologic treatment history with infusion dates.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).